Nova Leap Health Corp. Posts Record Q2 2026 Revenue, Income from Operating Activities and Adjusted EBITDA

Nova Leap posts record revenue and profit, reversing last year's net loss.

What the company is saying

Nova Leap Health Corp. frames its Q2 2026 results as a turning point, highlighting a 17.1% year-over-year revenue increase to $9,393,302 and record trailing twelve-month revenue of $33,597,305. The company emphasizes a 65.2% jump in Adjusted EBITDA to $954,836 and a swing to net income of $649,977 from a net loss of $484,008 in Q2 2025. Management underscores the acquisition of a Nova Scotia home care company for CAD$3,500,000 as evidence of its growth strategy in action. The announcement stresses strong gross margins at 40.3% and points to ongoing investment in Florida and Texas, along with anticipated organic expansion in Nova Scotia and New Hampshire. The tone is confident, focusing on realized improvements and operational momentum. Forward-looking statements are present but remain qualitative, with no specific financial targets or guidance disclosed.

What the data suggests

The disclosed numbers show a clear, broad-based improvement in financial performance. Revenue for Q2 2026 reached $9,393,302, up 17.1% from the prior year, while trailing twelve-month revenue set a new company record at $33,597,305. Adjusted EBITDA for the quarter increased by 65.2% to $954,836, and trailing twelve-month Adjusted EBITDA also hit a record at $2,595,350. Gross profit margin held steady at 40.3%, nearly unchanged from 40.2% a year earlier, indicating stable profitability. Income from operating activities more than doubled to $754,667, and the company moved from a net loss of $484,008 in Q2 2025 to net income of $649,977 in Q2 2026. Cash on hand was $1,441,635 at quarter-end, with $3,532,747 in outstanding loans and a debt-to-EBITDA ratio of 1.36x, suggesting manageable leverage. The acquisition of a Nova Scotia home care company was fully funded through a mix of debt and cash, with clear disclosure of amounts and terms. No per-share or segment-level data is provided, and future financial projections are absent.

Analysis

The announcement is primarily focused on realised, historical financial results, with all major claims (revenue, Adjusted EBITDA, net income, operating cash flow) supported by specific, period-over-period numerical data. The only forward-looking statements are qualitative and limited to anticipated continued investment and organic expansion, with no exaggerated projections or unsubstantiated targets. The acquisition disclosed is already completed and its funding sources are detailed, with no indication of large, speculative capital outlays for uncertain future returns. The language is proportionate to the evidence, and the company provides a full suite of profitability and cash flow metrics, allowing investors to assess the sustainability of growth. There is no material gap between narrative and evidence, and no signs of narrative inflation.

Risk flags

• ●Absence of per-share metrics and segment breakdowns limits the ability to assess profitability by geography or business line, which could mask underperformance in specific areas.
• ●Forward-looking statements about continued investment and expansion are qualitative only, with no disclosed financial targets or timelines, increasing uncertainty around future growth realization.
• ●Outstanding debt of $3,532,747 and a debt-to-EBITDA ratio of 1.36x are manageable but indicate ongoing leverage risk, particularly if acquisition-driven growth does not translate into sustained cash flow.
• ●Cash on hand of $1,441,635 appears adequate for near-term operations, but future acquisitions will rely on credit facilities, exposing the company to refinancing or interest rate risks if market conditions change.

Bottom line

Nova Leap Health Corp.'s Q2 2026 results show a decisive turnaround, with record revenue, sharply higher EBITDA, and a swing to net profitability. The company has executed a material acquisition and maintains stable gross margins, while leverage remains within a reasonable range. The narrative is credible, as all major claims are substantiated by detailed, period-over-period financial data. The lack of per-share, segment, or quantified forward guidance leaves some gaps for deeper analysis, and future growth depends on successful integration of acquisitions and organic expansion in new markets. Investors should focus on whether these trends persist in future quarters and watch for more granular disclosures or concrete financial targets. The most important takeaway is that the company has delivered tangible operational and financial improvements, but the sustainability of this trajectory will depend on disciplined execution and continued transparency.

Announcement summary

(TSXV: NLH) Nova Leap Health Corp. announced financial results for the quarter ended June 30, 2026, reporting Q2 2026 revenue of $9,393,302, a 17.1% increase over Q2 2025 revenue of $8,021,072. Trailing twelve-month revenue for the period from July 1, 2025 to June 30, 2026 was $33,597,305, the highest in the Company’s history. Q2 2026 Adjusted EBITDA was $954,836, up 65.2% from Q2 2025 Adjusted EBITDA of $577,907, and trailing twelve-month Adjusted EBITDA was $2,595,350, also a record. The Company generated income from operating activities in Q2 2026 of $754,667, an increase of 115.4% over Q2 2025, and recorded net income of $649,977 compared to a net loss of $484,008 in Q2 2025. On May 1, 2026, Nova Leap acquired a home care services company in Nova Scotia for total consideration of CAD$3,500,000, with CAD$3,200,000 paid in cash on closing and CAD$300,000 by promissory note. The Company had available cash of $1,441,635 as of June 30, 2026, and access to up to $3,050,000 in available credit for business acquisitions. The company projects continued investment in Florida and Texas and anticipates further organic expansion in Nova Scotia and New Hampshire.

Disagree with this article?